Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | HRH1 | P35367 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.39 |
| ▸ | HRH2 | P25021 | 2/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4508020 | 0.88 | KCNH2 (0.44) | GPR119HRH1HTR1ADRD4HTR2A | |
| SCHEMBL4516571 | 0.87 | GPR119 (0.40) | GPR119HRH1HTR1ADRD4HTR2A | |
| SCHEMBL4508018 | 0.87 | GPR119 (0.40) | GPR119HRH1HTR1ADRD4HTR2A | |
| SCHEMBL2954568 | 0.87 | KCNH2 (0.52) | GPR119HRH1KCNH2HRH2HRH3 | |
| SCHEMBL3121813 | 0.86 | GPR119 (0.48) | GPR119NAMPTEGLN2ARALDH1A1 | |
| SCHEMBL2956811 | 0.86 | GPR119 (0.41) | GPR119HRH1KCNH2HRH2NAMPT | |
| Hydrochloric Acid SCHEMBL4667417 | 0.85 | GPR119 (0.47) | GPR119NAMPTEGLN2ARALDH1A1 | |
| SCHEMBL3423966 | 0.85 | SIGMAR1 (0.45) | HRH1HTR1ADRD4HTR2AOPRM1 | |
| SCHEMBL2961116 | 0.84 | KCNH2 (0.44) | GPR119KCNH2EGLN2 | |
| SCHEMBL2962586 | 0.84 | HTR1A (0.47) | HRH1HTR1ADRD4HTR2AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772229-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB, (SE) | 2009-12-31 | — | — | US | disclosed |
| US-7351821-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2008-04-01 | — | — | US | disclosed |
| US-20070117799-A1 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB, SODERTALJE, SWEDEN | 2007-05-24 | — | — | US | disclosed |
| US-7217708-B2 | Cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-05-15 | — | — | US | disclosed |
| US-7164017-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2007-01-16 | — | — | US | disclosed |
| US-20060166980-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | US | disclosed |
| US-20060166979-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | US | disclosed |
| EP-1389212-B1 | 3,7-DIAZABICYCLO 3.3.1| FORMULATIONS AS ANTI-ARRYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| EP-1389213-B1 | 3,7-DIAZABICYCLO 3.3.1| FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1235831-B1 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-03-30 | — | — | EP | disclosed |
| US-20050037067-A1 | 3,7-Diazabicyclo [3.3.1]formulations as anti-arrhythmic compounds | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | US | disclosed |
| US-20040143000-A1 | 3,7-diazabicyclo [3.3.1] formulations as antiarhythmic compounds | ASTRAZENECA AB (SE) | 2004-07-22 | — | — | US | disclosed |
| US-20040132798-A1 | 3.7-Diazybicyclo [3.3.1] formulations as antiarrhythmic compounds | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | US | disclosed |
| EP-1389211-A1 | 3,7-DIAZYBICYCLO 3.3.1] FORMULATIONS AS ANTIARRHYTMIC COMPOUNDS | AstraZeneca AB (SE) | 2004-02-18 | — | — | EP | disclosed |
| EP-1389213-A1 | 3,7-DIAZABICYCLO 3.3.1] FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS | AstraZeneca AB (SE) | 2004-02-18 | — | — | EP | disclosed |
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB | 2003-08-14 | — | — | US | disclosed |
| US-6559143-B1 | Class III electrophysiological activity, drugs which prolong the trans-membrane action potential duration and refractoriness, without affecting cardiac conduction | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| WO-2002083687-A1 | 3,7-DIAZYBICYCLO [3.3.1] FORMULATIONS AS ANTIARRHYTMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083688-A1 | 3,7-DIAZABICYCLO [3.3.1] FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, RYR1 | GPR119 3836/4885HRH1 765/4885HTR1A 2954/4885 |
| US-20050037067-A1 | 3,7-Diazabicyclo [3.3.1]formulations as anti-arrhythmic compounds | CACNA1G, CACNA1I, CACNA1B | GPR119 2649/4885HRH1 1918/4885HTR1A 4023/4885 |
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, SCN1B | GPR119 2853/4885HRH1 970/4885HTR1A 3488/4885 |
| US-20060166979-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, RYR1, CACNA1E | GPR119 2719/4885HRH1 526/4885HTR1A 3302/4885 |
| US-20070117799-A1 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, RYR1, CACNA1E | GPR119 3115/4885HRH1 591/4885HTR1A 3566/4885 |
| US-20040132798-A1 | 3.7-Diazybicyclo [3.3.1] formulations as antiarrhythmic compounds | HCN3, CACNB3, TNNI3 | GPR119 3754/4885HRH1 3815/4885HTR1A 4380/4885 |
| US-20040143000-A1 | 3,7-diazabicyclo [3.3.1] formulations as antiarhythmic compounds | SCN3A, KCNH1, CACNA1G | GPR119 2007/4885HRH1 3026/4885HTR1A 2639/4885 |
| US-20060166980-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, RYR1, CACNA1E | GPR119 2719/4885HRH1 526/4885HTR1A 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.